Literature DB >> 24074962

Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff.

Celeste A Lemay1, Kathleen M Mazor, Terry S Field, Jennifer Donovan, Abir Kanaan, Becky A Briesacher, Sarah Foy, Leslie R Harrold, Jerry H Gurwitz, Jennifer Tjia.   

Abstract

BACKGROUND/
OBJECTIVES: Antipsychotic use is common in US nursing homes, despite evidence of increased risk of morbidity and mortality, and limited efficacy in older adults with dementia. Knowledge, attitudes, and beliefs regarding antipsychotic use among nursing home staff are unclear. The study aim was to describe nursing home leadership and direct care staff members' knowledge of antipsychotic risks, beliefs and attitudes about the effectiveness of antipsychotics and nonpharmacologic management of dementia-related behaviors, and perceived need for evidence-based training about antipsychotic medication safety. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Survey of leadership and direct care staff of nursing homes in Connecticut was conducted in June 2011. Questionnaire domains included knowledge of antipsychotic risks, attitudes about caring for residents with dementia, satisfaction with current behavior management training, beliefs about antipsychotic effectiveness, and need for staff training about antipsychotics and behavior management.
RESULTS: A total of 138 nursing home leaders and 779 direct care staff provided useable questionnaires. Only 24% of nursing home leaders identified at least 1 severe adverse effect of antipsychotics; 13% of LPNs and 12% of RNs listed at least 1 severe adverse effect. Fifty-six percent of direct care staff believed that medications worked well to manage resident behavior. Leaders were satisfied with the training that staff received to manage residents with challenging behaviors (62%). Fifty-five percent of direct care staff felt that they had enough training on how to handle difficult residents; only 37% felt they could do so without using medications.
CONCLUSIONS: Findings suggest that a comprehensive multifaceted intervention designed for nursing homes should aim to improve knowledge of antipsychotic medication risks, change beliefs about appropriateness and effectiveness of antipsychotics for behavior management, and impart strategies and approaches for nonpharmacologic behavior management.
Copyright © 2013 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical antipsychotics; evidenced-based prescribing; nursing homes

Mesh:

Substances:

Year:  2013        PMID: 24074962     DOI: 10.1016/j.jamda.2013.08.009

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  13 in total

1.  [Choosing Wisely. A model for the German health care system?].

Authors:  M Gogol
Journal:  Z Gerontol Geriatr       Date:  2014-01       Impact factor: 1.281

Review 2.  Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia.

Authors:  Stephanie L Harrison; Monica Cations; Tiffany Jessop; Sarah N Hilmer; Mouna Sawan; Henry Brodaty
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

3.  Educating Nursing Home Staff in Dementia Sensitive Communication: Impact on Antipsychotic Medication Use.

Authors:  Clarissa Shaw; Kristine N Williams; Yelena Perkhounkova
Journal:  J Am Med Dir Assoc       Date:  2018-12       Impact factor: 4.669

4.  Use of atypical antipsychotics in nursing homes and pharmaceutical marketing.

Authors:  Camilla B Pimentel; Jennifer L Donovan; Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Abir O Kanaan; Celeste A Lemay; Kathleen M Mazor; Jennifer Tjia; Becky A Briesacher
Journal:  J Am Geriatr Soc       Date:  2015-02       Impact factor: 5.562

Review 5.  Relationship between Organizational Culture and the Use of Psychotropic Medicines in Nursing Homes: A Systematic Integrative Review.

Authors:  Mouna Sawan; Yun-Hee Jeon; Timothy F Chen
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

6.  Reliability and Validity Testing of the Assessment of the Environment for Person-Centered Management of BPSD and Assessment of Policies for Person-Centered Management of BPSD Measures.

Authors:  Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Shijun Zhu; Jeanette Ellis; Liza Behrens; Karen Eshraghi; Nicole Viviano; Ying-Ling Jao
Journal:  J Aging Environ       Date:  2020-01-28

7.  Testing the evidence integration triangle for implementation of interventions to manage behavioral and psychological symptoms associated with dementia: Protocol for a pragmatic trial.

Authors:  Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Jeanette Ellis; Liza Behrens; Nina M Flanagan; Karen J Eshraghi; Shijun Zhu
Journal:  Res Nurs Health       Date:  2018-02-27       Impact factor: 2.228

8.  Impact of a Videoconference Educational Intervention on Physical Restraint and Antipsychotic Use in Nursing Homes: Results From the ECHO-AGE Pilot Study.

Authors:  Stephen E Gordon; Alyssa B Dufour; Sara M Monti; Melissa L P Mattison; Angela G Catic; Cindy P Thomas; Lewis A Lipsitz
Journal:  J Am Med Dir Assoc       Date:  2016-05-06       Impact factor: 4.669

9.  Relationship between the presence of baccalaureate-educated RNs and quality of care: a cross-sectional study in Dutch long-term care facilities.

Authors:  Ramona Backhaus; Erik van Rossum; Hilde Verbeek; Ruud J G Halfens; Frans E S Tan; Elizabeth Capezuti; Jan P H Hamers
Journal:  BMC Health Serv Res       Date:  2017-01-19       Impact factor: 2.655

10.  Implementation of the Evidence Integration Triangle for behavioral and psychological symptoms of dementia (EIT-4-BPSD) in care communities.

Authors:  Barbara Resnick; Kimberly Van Haitsma; Ann Kolanowski; Elizabeth Galik; Marie Boltz; Shijun Zhu; Jeanette Ellis; Liza Behrens; Karen Eshraghi
Journal:  Nurs Outlook       Date:  2021-07-28       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.